MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
35.05
+0.72
+2.10%
After Hours: 35.05 0 0.00% 17:39 04/13 EDT
OPEN
34.31
PREV CLOSE
34.33
HIGH
35.64
LOW
34.31
VOLUME
772.26K
TURNOVER
--
52 WEEK HIGH
40.22
52 WEEK LOW
6.89
MARKET CAP
2.07B
P/E (TTM)
-301.3758
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STOK last week (0406-0410)?
Weekly Report · 18h ago
Did Stoke’s New R&D Chair Signal a Tighter Late-Stage Focus for STOK’s Pipeline Strategy?
Simply Wall St · 5d ago
Stoke Therapeutics CEO to present at Needham Virtual Healthcare Conference
Reuters · 5d ago
Stoke Therapeutics director Clare Kahn files initial beneficial ownership statement
Reuters · 6d ago
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight
TipRanks · 6d ago
Stoke Therapeutics appoints Clare Kahn to board of directors
Reuters · 6d ago
STOKE THERAPEUTICS APPOINTS CLARE KAHN, PH.D., TO ITS BOARD OF DIRECTORS
Reuters · 6d ago
*Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Its Bd of Directors
Dow Jones · 6d ago
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.